이식용 분자진단

Molecular Diagnostics for Transplant Market Research Report Forecast till 2030

Market Overview

Molecular Diagnostics for Transplant Market is anticipated to register a CAGR of 8.91% during the review period.

Expanding pervasiveness of irresistible illnesses, rising number of transplant systems, and progressions in molecular symptomatic methods are reinforcing the market development.

There has been a rising pervasiveness of irresistible illnesses attributable to different factors, for example, environmental change, quick urbanization, microbial development, among others. Exceptional consideration should be accepted before transplantation as a transplant patient can get any kind of contamination brought about by microorganisms, infections, organisms and parasites. These incorporate flu infection contamination, urinary lot disease, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr infection, Human herpesvirus 6, among a few others. Besides, expanding antimicrobial obstruction is likewise a reason for serious concern and has been adding to the rising predominance of irresistible infection. For example, as per the Communities for Infectious prevention and Anticipation, more than 2.8 million antimicrobial-safe contaminations happen in the US every year. Subsequently, expanding commonness of irresistible sickness has driven the interest for execution of exhaustive molecular diagnostics in transplantation, in this manner, driving the market.

Market Segmentation

The Molecular Diagnostics for Transplant Market, based on product is segmented into reagents & kits, instruments, and services & software.

Based on technology the market is divided into polymerase chain reaction (PCR), sequencing, microarray, and others.

Based on end user, the market has been classified into the hospitals and transplant centers, research laboratories & academic institutes, and others.

Regional Insights

North America molecular diagnostics for transplant market represented the biggest piece of the pie in 2021, because of rising interest innovation development and expanding rates of ongoing sicknesses that lead to an expansion in organ transplants. As per research, the quantity of kidneys, liver, heart, lung, pancreas, and digestive tract transplants is expanding in the US, while the quantity of kidney transplants is expanding in Canada.

Europe molecular diagnostics for transplant market represents the second-biggest market attributable to the rising pervasiveness of constant infections, including kidney, cardiovascular sicknesses (CVD), and respiratory illnesses. Headways in molecular diagnostics have worked on the recognizable proof and comprehension of explicit quality imperfections for the suitable organ transplant in kidney, heart, and lung disappointment. CVD illnesses are impacted by variables, for example, atherosclerosis, blood clusters, diabetes, a stationary way of life, and weight, which might prompt heart disappointment.

The Asia-Pacific molecular diagnostics for transplant market is supposed to develop at a critical share from 2022 to 2030. The region's developing geriatric populace requests organ transplantation, which might change according to organ disappointment. In 2020, as per the World Financial Forum, China, India, and Japan had the most established populaces universally. Moreover, it has been assessed that by 2050, one of every four matured individuals will be living in the region.

Major Players

Key Companies in the Molecular Diagnostics for Transplant Market are Thermo Fisher Scientific Inc. (US), Abbott Laboratories, Inc. (US), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), BioMerieux SA (France), Hoffmann-La Roche Ltd. (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), and Others.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
  • 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA MINING
• 3.3 SECONDARY RESEARCH
• 3.4 PRIMARY RESEARCH
  • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES
  • 4.2.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTIC TECHNIQUES
  • 4.2.3 INCREASING NUMBER OF TRANSPLANT PROCEDURES
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT RULES AND REGULATIONS FOR PRODUCT APPROVAL
  • 4.3.2 DEARTH OF SKILLED LABOR
• 4.4 OPPORTUNITIES
  • 4.4.1 GROWING PUBLIC AWARENESS ABOUT ORGAN DONATION AND TRANSPLANTATION

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D AND DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES SERVICES AND REVIEW
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON GLBOAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • 5.3.1 IMPACT ON DEMAND
  • 5.3.2 IMPACT ON SUPPLY CHAIN
  • 5.3.3 IMPACT ON KEY PLAYERS
• 5.4 QUALITATIVE OVERVIEW FOR INFECTIOUS DISEASE VIRUSES
  • 5.4.1 CYTOMEGALOVIRUS (CMV)
  • 5.4.2 EPSTEIN-BARR VIRUS (EBV)
  • 5.4.3 BK POLYOMAVIRUS (BKV)
  • 5.4.4 HUMAN HERPESVIRUS (HHV-6)
  • 5.4.5 ADENOVIRUS
  • 5.4.6 HERPES SIMPLEX VIRUS (HSV)
  • 5.4.7 PARVOVIRUS
  • 5.4.8 JOHN CUNNINGHAM VIRUS (JCV)
  • 5.4.9 HEPATITIS E VIRUS (HEV)
  • 5.4.10 OTHERS

6 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 REAGENTS & KITS
• 6.3 INSTRUMENTS
• 6.4 SERVICES & SOFTWARE

7 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY

• 7.1 OVERVIEW
• 7.2 POLYMERASE CHAIN REACTION (PCR)
• 7.3 SEQUENCING
• 7.4 MICROARRAY
• 7.5 OTHERS

8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS AND TRANSPLANT CENTERS
• 8.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
• 8.4 OTHERS

9 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 JAPAN
  • 9.4.2 CHINA
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • 10.6.2 PARTNERSHIP/AGREEMENT
  • 10.6.3 MERGER /ACQUISTION
• 10.7 FINANCIAL MATRIX
  • 10.7.1 SALES (USD MILLION),
  • 10.7.2 R&D EXPENDITURE (USD MILLION),

11 COMPANY PROFILE

• 11.1 BIOMERIEUX SA
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCT OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 THERMO FISHER SCIENTIFIC INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCT/SERVICE OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 CEPHEID
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCT/SERVICE OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 ALTONA DIAGNOSTICS GMBH
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 ELITECHGROUP
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 F. HOFFMANN-LA ROCHE LTD
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 HOLOGIC, INC.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS/SERVICES OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 QIAGEN N.V.
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 BECTON, DICKINSON AND COMPANY
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 SWOT ANALYSIS
  • 11.9.6 KEY STRATEGIES
• 11.10 ABBOTT
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS